Citations

Clear

941 citation(s) found for "Tefferi, A".

MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
Tefferi, Ayalew , Gangat, Naseema , Pardanani, Animesh , Lasho, Terra L. , Guglielmelli, Paola , Ketterling, Rhett P. , Vannucchi, Alessandro M.

Mayo Clinic

Journal of Clinical Oncology | April 30, 2018 | Volume: 36 | Issue: 17 | Pages: 1769-1770

10.1200/jco.2018.78.9867 | PMID 29708808 Get It

The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes
Penna, Domenico , Nicolosi, Maura , Vallapureddy, Rangit, Hanson, Curtis A. , Pardanani, Animesh , Gangat, Naseema , Tefferi, Ayalew , Vallapureddy, Rangit R, Szuber, Natasha , Lasho, Terra L. , Gangat, Naseema , Tefferi, Ayalew , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | April 16, 2018 | Volume: 93 | Issue: 7 | Pages: No page available

10.1002/ajh.25114 | PMID 29659079 Get It

Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates
Hoversten, Katherine P., Vallapureddy, Rangit, Finke, Christy M. , Hanson, Curtis A. , Gangat, Naseema , Tefferi, Ayalew , Patnaik, Mrinal M. , Hoversten, Katherine, Hanson, Curtis, Patnaik, Mrinal , Lasho, Terra L. , Ketterling, Rhett P.

Mayo Clinic

Leukemia & Lymphoma | March 27, 2018 | Volume: 59 | Issue: 12 | Pages: 2998-3001

10.1080/10428194.2018.1452212 | PMID 29582697 Get It

U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates
Tefferi, Ayalew , Mudireddy, Mythri , Finke, Christy M. , Nicolosi, Maura , Hanson, Curtis A. , Patnaik, Mrinal M. , Pardanani, Animesh , Gangat, Naseema , Lasho, Terra L. , Patnaik, Mrinal , Gangat, Naseema

Mayo Clinic

American Journal of Hematology | March 8, 2018 | Volume: 93 | Issue: 6 | Pages: No page available

10.1002/ajh.25084 | PMID 29516544 Get It

Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management
Elliott, Michelle A. , Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | March 7, 2018 | Volume: 93 | Issue: 4 | Pages: 578-587

10.1002/ajh.24983 | PMID 29512199 Get It

AbstractDisease Overview and DiagnosisChronic neutrophilic leukemia (CNL) is a potentially aggressive myeloproliferative neoplasm, for which current WHO diagnostic criteria include leukocytosis of ≥ 25 x 109/L of which ≥ 80% are neutrophils, with < 10% circulating neutrophil precursors with blasts rarely observed. In addition, there is no dysplasia, nor clinical or molecular criteria for other myeloproliferative neoplasms.Update on DiagnosisPreviously the diagnosis of CNL was often as one of exclusion based on no identifiable cause for physiologic neutrophilia in patients fulfilling the aforementioned criteria. The 2016 WHO classification now recognizes somatic activating mutations of CSF3R (most commonly CSF3RT618I) as diagnostic, allowing for an accurate diagnosis for the majority of suspected cases through molecular testing. These mutations are primary driver mutations, accounting for the characteristic clinical phenotype and potential susceptibility to molecularly targeted therapy.Risk StratificationConcurrent mutations, common to myeloid neoplasms and their precursor states, most frequently in SETBP1 and ASXL1, are frequent and appear to be of prognostic significance. Although data are evolving on the full genomic profile, the rarity of CNL has delayed complete understanding of its full molecular pathogenesis and individual patient prognosis.
Prevention of liver cancer with new curative hepatitis C antivirals: Real‐world challenges
Soriano, Vincent , Tefferi, Ayalew , Soriano, Vicente

Mayo Clinic

Cancer | February 27, 2018 | Volume: 124 | Issue: 8 | Pages: 1647-1649

10.1002/cncr.31291 | PMID 29486060 Get It

New antiviral therapies cure most patients with hepatitis C and prevent the development of cirrhosis and hepatocellular carcinoma. The major challenges for global hepatitis C virus eradication are the identification of patients with chronic hepatitis C, referrals to treatment, and elevated drug prices. See also pages 1644‐46.
Targeted next-generation sequencing in blast phase myeloproliferative neoplasms
Mudireddy, Mythri , Finke, Christy M. , Hanson, Curtis A. , Begna, Kebede H. , Patnaik, Mrinal M. , Gangat, Naseema , Pardanani, Animesh , Tefferi, Ayalew , Tefferi, Ayalew , Lasho, Terra L. , Ketterling, Rhett P. , Szuber, Natasha

Mayo Clinic

Blood Advances | February 21, 2018 | Volume: 2 | Issue: 4 | Pages: 370-380

10.1182/bloodadvances.2018015875 | PMID 29467191 Get It

Key Points Mutation patterns in blast phase MPN, including paired sample analysis, point to specific mutations with potential pathogenetic relevance. RUNX1 mutations predict inferior survival in blast phase MPN, independent of specific treatment strategies.
Mayo CALR mutation type classification guide using alpha helix propensity
Finke, Christy M. , Tischer, Alexander , Pardanani, Animesh , Tefferi, Ayalew , Lasho, Terra L. , Tefferi, Ayalew , Tischer, Alexander

Mayo Clinic

American Journal of Hematology | February 9, 2018 | Volume: 93 | Issue: 5 | Pages: No page available

10.1002/ajh.25065 | PMID 29424450 Get It

Mutations and prognosis in myelodysplastic syndromes: karyotype‐adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model
Gangat, Naseema , Mudireddy, Mythri , Finke, Christy M. , Nicolosi, Maura , Patnaik, Mrinal M. , Pardanani, Animesh , Hanson, Curtis A. , Tefferi, Ayalew , Lasho, Terra L. , Szuber, Natasha , Patnaik, Mrinal , Tefferi, Ayalew , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | February 8, 2018 | Volume: 93 | Issue: 5 | Pages: 691-697

10.1002/ajh.25064 | PMID 29417633 Get It

AbstractTo develop a genetic risk model for primary myelodysplastic syndromes (MDS), we queried the prognostic significance of next‐generation sequencing (NGS)‐derived mutations, in the context of the Mayo cytogenetic risk stratification, which includes high‐risk (monosomal karyotype; MK), intermediate‐risk (non‐MK, classified as intermediate/poor/very poor, per the revised international prognostic scoring system; IPSS‐R), and low‐risk (classified as good/very good, per IPSS‐R). Univariate analysis in 300 consecutive patients with primary MDS identified TP53, RUNX1, U2AF1, ASXL1, EZH2, and SRSF2 mutations as “unfavorable” and SF3B1 as “favorable” risk factors for survival; for the purposes of the current study, the absence of SF3B1 mutation was accordingly dubbed as an “adverse” mutation. Analysis adjusted for age and MK, based on our previous observation of significant clustering between MK and TP53 mutations, confirmed independent prognostic contribution from RUNX1, ASXL1, and SF3B1 mutations. Multivariable analysis that included age, the Mayo cytogenetics risk model and the number of adverse mutations resulted in HRs (95% CI) of 5.3 (2.5‐10.3) for presence of three adverse mutations, 2.4 (1.6‐3.7) for presence of two adverse mutations, 1.5 (1.02‐2.2) for presence of one adverse mutation, 5.6 (3.4‐9.1) for high‐risk karyotype, 1.5 (1.1‐2.2) for intermediate‐risk karyotype and 2.4 (1.8‐3.3) for age >70 years; HR‐weighted risk point assignment generated a three‐tiered genetic risk model: high (N = 65; 5‐year survival 2%), intermediate (N = 100; 5‐year survival 18%), and low (N = 135; 5‐year survival 56%). The current study provides a practically simple risk model in MDS that is based on age, karyotype, and mutations only.